搜索公司,投資者……

預測你的未來投資

資產/投資管理
fairmountfunds.com

投資

9

投資退出

1

費爾蒙特基金管理

費爾蒙特基金管理是一個費城,賓夕法尼亞州的資產管理公司。

總部的位置

2001年市場St 2500套房

費城,賓夕法尼亞州,19103年,

美國

想告知投資者類似費爾蒙特基金管理關於你的公司嗎?

提交你的分析師簡報在投資者麵前,CB Insights的平台上的客戶和合作夥伴。188bet游戏

最新的費爾蒙特基金管理新聞

典範療法啟動第一剝離,遠地點療法,促進小說治療炎症和免疫條件

2022年12月7日

新聞分享這篇文章提供的共享驗證本文裏程碑典範的戰略迅速提供一流的生物治療病人沃爾瑟姆,質量。,Dec. 7, 2022 /PRNewswire/ -- Paragon Therapeutics, a biotechnology company dedicated to discovering and developing best-in-class biologics for a range of diseases with high unmet need, today announced the launch of Apogee Therapeutics, LLC, its first spinout. Apogee is advancing a pipeline of product candidates discovered and developed at Paragon that have potential to reach millions of people living with inflammatory and immunological disorders. Building on validated protein engineering technologies, Paragon leverages cutting-edge science and technology to rapidly identify and propel biologics from ideation to the clinic. The company's process combines high-throughput screening systems and optimization techniques to isolate the best possible drug candidates with a CMC model that enables quick and reliable production—aimed at delivering targeted treatment options to patients. "At Paragon, we are thrilled to announce the launch of Apogee Therapeutics as our first independent company, and we are confident that the Apogee team is well positioned to execute and demonstrate therapeutic leadership in areas of high unmet need," said K. Evan Thompson, Ph.D., Chief Operating Officer of Paragon. "The debut of Apogee validates our approach to advancing best-in-class biologics to patients through a range of opportunities, from new company creation and strategic partnerships to shaping programs in-house with our experienced and proven team." Apogee was founded in 2022 by Fairmount and Venrock Healthcare Capital Partners and has raised $169 million in financing to date, including an oversubscribed $149 million Series B round co-led by Deep Track Capital and RTW Investments, LP. Under the guidance of CEO Michael Henderson, M.D., the funding is expected to support key leadership, science, and clinical team hires and progress its lead pipeline program, APG777, to the clinic in 2023. As part of its agreement with Paragon, Apogee has an option for exclusive development and commercial rights to a suite of top-tier antibodies specifically engineered to target some of the largest and highest unmet needs in inflammatory and immunological conditions. "Paragon has mastered the design and development of transformative therapies that meet the highest needs for inflammatory and immune diseases," said Dr. Henderson. "We are excited to build on their work to deliver life-changing therapies that improve patients' lives." Paragon was founded in 2021 by Fairmount and is led by a team of innovators with deep expertise in biologics engineering and development. The company's collaboration with FairJourney Biologics expands its reach and capabilities through dedicated antibody discovery experts and resources. In addition to those partnered with Apogee, Paragon is currently advancing multiple differentiated programs for a range of diseases. About Paragon Therapeutics Paragon Therapeutics, Inc. is a biotechnology company leveraging cutting-edge science and technology to identify and propel best-in-class biologics into the clinic for a range of human diseases with high unmet needs. The company rapidly advances therapies through a range of opportunities, from new company creation and strategic partnerships to shaping programs in-house. Founded by Fairmount in 2021 as a joint venture with FairJourney Biologics, Paragon Therapeutics is based in Waltham, Mass. For more information, please visit www.paragontherapeutics.com . About Apogee Therapeutics Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee is building a pipeline of product candidates targeting clinically validated biology and well-established development pathways. Based in San Francisco, Calif., Apogee was founded in 2022 by Fairmount and Venrock Healthcare Capital Partners and is backed by leading healthcare investors. To learn more visit: www.apogeetherapeutics.com . About Fairmount Fairmount Funds Management LLC is a Philadelphia-based investment firm dedicated to investing in promising new therapies pursued by biotechnology and life science companies. SOURCE Paragon Therapeutics

費爾蒙特基金管理投資

9投資

費爾蒙特基金管理9投資他們最新的投資活躍療法作為他們的一部分2023年2月2日

CBI的標誌

費爾蒙特基金管理投資活動

投資表

日期

公司

新的嗎?

共同投資者

來源

2/23/2023

活躍療法

165美元

是的

2

12/7/2022

B係列

訂閱看到更多

99美元

訂閱看到更多

10

11/7/2022

B係列

訂閱看到更多

99美元

訂閱看到更多

10

4/21/2022

一個係列

訂閱看到更多

99美元

訂閱看到更多

10

1/1/2022

一個係列

訂閱看到更多

99美元

訂閱看到更多

10

日期

2/23/2023

12/7/2022

11/7/2022

4/21/2022

1/1/2022

B係列

B係列

一個係列

一個係列

公司

活躍療法

訂閱看到更多

訂閱看到更多

訂閱看到更多

訂閱看到更多

165美元

99美元

99美元

99美元

99美元

新的嗎?

是的

訂閱看到更多

訂閱看到更多

訂閱看到更多

訂閱看到更多

共同投資者

來源

2

10

10

10

10

費爾蒙特基金管理投資退出

1投資退出

費爾蒙特基金管理1投資組合退出。他們最新的投資退出Nuvalent 2021年7月29日

日期

退出

公司

估值
提交的估值公司,采自國家申請或者新聞,由VentureSource的提供,或基於比較數據的估值模型。

收購者

來源

7/29/2021

首次公開募股

99美元

公共

4

日期

7/29/2021

退出

首次公開募股

公司

估值

99美元

收購者

公共

來源

4

發現正確的解決方案為您的團隊

CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。

請求一個演示

CBI的網站通常使用一些餅幹,使更好的相互作用我們的網站和服務。使用這些餅幹,這可能是存儲在你的設備上,允許我們的改進和定製你的經曆。你可以閱讀更多關於你的餅幹的選擇在我們的隱私政策在這裏。繼續使用這個你同意這些選擇。

Baidu
map